Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Anıl Cengiz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation.
Abstract (Originalsprache)
Aims
To discover alternative dosing regimens of incretin mimetics that simultaneously reduce costs and maintain weight loss efficacy. As a secondary objective, we used our results to explore how allocating a limited incretin mimetics budget could affect public health on a national scale. Materials and Methods We used mathematical modelling and simulation of semaglutide and tirzepatide to investigate dosing regimens which have not yet been studied clinically. For semaglutide, we used a recent pharmacokinetic (PK) and pharmacodynamic (PD) model. For tirzepatide, we used a recent PK model and modelled PD by reparameterizing the semaglutide PD model to fit tirzepatide clinical data.
Results
Reducing dose frequency does not commensurately reduce weight loss. For example, merely switching from one dose per week (q1wk) to one dose every 2 weeks (q2wk) maintains roughly 75% of the weight loss. Furthermore, if the decrease in dose frequency involves an appropriate increase in dose size, then approximately 100% of the weight loss is maintained. In addition, we compared offering incretin mimetics to (1) a fraction of obese US adults with q1wk dosing versus (2) twice as many obese US adults with q2wk dosing. Though scenarios (1) and (2) require the same budget, our analysis suggests that (2) reduces national obesity and mortality to a much greater degree.
Conclusion
Our study highlights the potential utility of alternative dosing regimens of incretin mimetics. Compared with standard once‐weekly dosing, costs can be halved and weight loss maintained. These cost‐saving results have implications for patients, physicians, insurers, and governments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mathematics, University of Utah, Salt Lake City, Utah, USA.
- Tono Health, Brooklyn, New York, USA.
ORCID-Profile: Anıl Cengiz, Calvin C Wu, Sean D Lawley
Förderung
- National Science Foundation
Zitieren
APA
Cengiz, A., Wu, C. C., & Lawley, S. D. (2025). Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16229
Vancouver
Cengiz A, Wu CC, Lawley SD. Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16229
BibTeX
@article{Cengiz2025,
author = {Cengiz, Anıl and Wu, Calvin C and Lawley, Sean D},
title = {Alternative dosing regimens of GLP ‐1 receptor agonists may reduce costs and maintain weight loss efficacy},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16229}
}
EUVIMED